Akari Therapeutics Plc - Ordinary Shares, $0.000000005 par value (AKTX)

CUSIP: 00972G207

Q3 2025 13F Holders as of 30 Sep 2025

Type / Class
Equity / Ordinary Shares, $0.000000005 par value
Shares outstanding
94,284,567,045
Total 13F shares
1,170,067
Share change
+619,327
Total reported value
$1,181,319
Price per share
$1.01
Number of holders
16
Value change
+$593,371
Number of buys
5
Number of sells
5

Sponsored

Quarterly Holders Quick Answers

What is CUSIP 00972G207?
CUSIP 00972G207 identifies AKTX - Akari Therapeutics Plc - Ordinary Shares, $0.000000005 par value in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Top shareholders of AKTX - Akari Therapeutics Plc - Ordinary Shares, $0.000000005 par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Holder Source Role / Reporting Ownership % Shares Holdings Value 12M Net Δ As of Details
SABBY MANAGEMENT, LLC
13F
Company
0%
179,785
$210,330 30 Jun 2025
13F
Palo Alto Investors LP
13F
Company
0%
146,024
$170,834 30 Jun 2025
13F
HighTower Advisors, LLC
13F
Company
0%
79,236
$92,698 30 Jun 2025
13F
Omnia Family Wealth, LLC
13F
Company
0%
62,690
$73,341 30 Jun 2025
13F
Cerity Partners LLC
13F
Company
0%
23,643
$27,660 30 Jun 2025
13F
Cresset Asset Management, LLC
13F
Company
0%
18,408
$21,536 30 Jun 2025
13F
RENAISSANCE TECHNOLOGIES LLC
13F
Company
0%
17,415
$20,374 30 Jun 2025
13F
Accent Capital Management, LLC
13F
Company
0%
10,000
$11,699 30 Jun 2025
13F
NewEdge Advisors, LLC
13F
Company
0%
6,800
$7,955 30 Jun 2025
13F
EverSource Wealth Advisors, LLC
13F
Company
0%
4,377
$5,121 30 Jun 2025
13F
UBS Group AG
13F
Company
0%
2,154
$2,520 30 Jun 2025
13F
Torsten Hombeck
3/4/5
CFO
mixed-class rows
200,400
mixed-class rows
$468 20 Mar 2025
BANK OF AMERICA CORP /DE/
13F
Company
0%
150
$175 30 Jun 2025
13F
Truvestments Capital LLC
13F
Company
0%
50
$59 30 Jun 2025
13F
Cornerstone Planning Group LLC
13F
Company
0%
5
$5 30 Jun 2025
13F
MORGAN STANLEY
13F
Company
0%
3
$4 30 Jun 2025
13F
Rachelle Suzanne Jacques
3/4/5
Chief Executive Officer, Director
class O/S missing
1,018,027,792
26 Apr 2024
Wendy F. Dicicco
3/4/5
Interim CFO
class O/S missing
158,473,915
01 May 2024
Donald A. Williams
3/4/5
Director
mixed-class rows
25,000,000
mixed-class rows
28 Jun 2024
Michael Grissinger
3/4/5
Director
mixed-class rows
25,000,000
mixed-class rows
28 Jun 2024
Mohamed Wa'El Ahmed Hashad
3/4/5
Director
class O/S missing
5,000,000
28 Jun 2024

Institutional Holders of Akari Therapeutics Plc - Ordinary Shares, $0.000000005 par value (AKTX) as of Q3 2025

As of 30 Sep 2025, Akari Therapeutics Plc - Ordinary Shares, $0.000000005 par value (AKTX) was held by 16 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 1,170,067 shares. The largest 10 holders included Cresset Asset Management, LLC, Palo Alto Investors LP, HighTower Advisors, LLC, Omnia Family Wealth, LLC, Cerity Partners LLC, Virtu Financial LLC, TWO SIGMA SECURITIES, LLC, Independent Advisor Alliance, Accent Capital Management, LLC, and NewEdge Advisors, LLC. This page lists 16 institutional shareholders reporting positions in this security for the Q3 2025 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period

Compare Q3 2025 vs Q2 2025 Across Filers

Q2 2025 holders
15
Q3 2025 holders
16
Holder diff
1
Investor Q2 2025 Shares Q3 2025 Shares Share Diff Share Chg % Q2 2025 Value $ Q3 2025 Value $ Value Diff $ Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.